Bradycor

Bradycor

A proprietary bradykinin antagonist, which made it to Phase II clinical trials for treating inflammation—e.g., for systemic inflammatory response syndrome (SIRS)—and Four Corners hantavirus infections. The drug sponsor ended trials in the mid-1990s.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.